These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. G-CSF prevents the progression of structural disintegration of white matter tracts in amyotrophic lateral sclerosis: a pilot trial. Duning T; Schiffbauer H; Warnecke T; Mohammadi S; Floel A; Kolpatzik K; Kugel H; Schneider A; Knecht S; Deppe M; Schäbitz WR PLoS One; 2011 Mar; 6(3):e17770. PubMed ID: 21423758 [TBL] [Abstract][Full Text] [Related]
5. Preliminary investigation of effect of granulocyte colony stimulating factor on amyotrophic lateral sclerosis. Zhang Y; Wang L; Fu Y; Song H; Zhao H; Deng M; Zhang J; Fan D Amyotroph Lateral Scler; 2009; 10(5-6):430-1. PubMed ID: 19922135 [TBL] [Abstract][Full Text] [Related]
6. Granulocyte-colony stimulating factor administration for neurological improvement in patients with postrehabilitation chronic incomplete traumatic spinal cord injuries: a double-blind randomized controlled clinical trial. Derakhshanrad N; Saberi H; Yekaninejad MS; Joghataei MT; Sheikhrezaei A J Neurosurg Spine; 2018 Jul; 29(1):97-107. PubMed ID: 29701561 [TBL] [Abstract][Full Text] [Related]
7. Intrathecal upregulation of granulocyte colony stimulating factor and its neuroprotective actions on motor neurons in amyotrophic lateral sclerosis. Tanaka M; Kikuchi H; Ishizu T; Minohara M; Osoegawa M; Motomura K; Tateishi T; Ohyagi Y; Kira J J Neuropathol Exp Neurol; 2006 Aug; 65(8):816-25. PubMed ID: 16896315 [TBL] [Abstract][Full Text] [Related]
8. Effects of continuous high-dose G-CSF administration on hematopoietic stem cell mobilization and telomere length in patients with amyotrophic lateral sclerosis - a pilot study. Iberl S; Meyer AL; Müller G; Peters S; Johannesen S; Kobor I; Beier F; Brümmendorf TH; Hart C; Schelker R; Herr W; Bogdahn U; Grassinger J Cytokine; 2019 Aug; 120():192-201. PubMed ID: 31100684 [TBL] [Abstract][Full Text] [Related]
9. Repeated courses of granulocyte colony-stimulating factor in amyotrophic lateral sclerosis: clinical and biological results from a prospective multicenter study. Chiò A; Mora G; La Bella V; Caponnetto C; Mancardi G; Sabatelli M; Siciliano G; Silani V; Corbo M; Moglia C; Calvo A; Mutani R; Rutella S; Gualandi F; Melazzini M; Scimè R; Petrini M; Bondesan P; Garbelli S; Mantovani S; Bendotti C; Tarella C; Muscle Nerve; 2011 Feb; 43(2):189-95. PubMed ID: 21254083 [TBL] [Abstract][Full Text] [Related]
10. Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: Grade 3, requiring assistance for eating, excretion or ambulation). WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 18 STUDY GROUP Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):40-48. PubMed ID: 28872915 [TBL] [Abstract][Full Text] [Related]
11. Consistent bone marrow-derived cell mobilization following repeated short courses of granulocyte-colony-stimulating factor in patients with amyotrophic lateral sclerosis: results from a multicenter prospective trial. Tarella C; Rutella S; Gualandi F; Melazzini M; Scimè R; Petrini M; Moglia C; Ulla M; Omedé P; Bella VL; Corbo M; Silani V; Siciliano G; Mora G; Caponnetto C; Sabatelli M; Chiò A; Cytotherapy; 2010; 12(1):50-9. PubMed ID: 19878077 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of EH301 for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled human pilot study. de la Rubia JE; Drehmer E; Platero JL; Benlloch M; Caplliure-Llopis J; Villaron-Casales C; de Bernardo N; AlarcÓn J; Fuente C; Carrera S; Sancho D; GarcÍa-Pardo P; Pascual R; JuÁrez M; Cuerda-Ballester M; Forner A; Sancho-Castillo S; Barrios C; Obrador E; Marchio P; Salvador R; Holmes HE; Dellinger RW; Guarente L; Estrela JM Amyotroph Lateral Scler Frontotemporal Degener; 2019 Feb; 20(1-2):115-122. PubMed ID: 30668199 [TBL] [Abstract][Full Text] [Related]
13. NurOwn, phase 2, randomized, clinical trial in patients with ALS: Safety, clinical, and biomarker results. Berry JD; Cudkowicz ME; Windebank AJ; Staff NP; Owegi M; Nicholson K; McKenna-Yasek D; Levy YS; Abramov N; Kaspi H; Mehra M; Aricha R; Gothelf Y; Brown RH Neurology; 2019 Dec; 93(24):e2294-e2305. PubMed ID: 31740545 [TBL] [Abstract][Full Text] [Related]